|Videos|January 4, 2023

Dr. Tanya Dorff on latest progress with PARP inhibitors in mCRPC

“The bulk of what we’re all grappling with are these new data for combining PARP inhibitors with androgen receptor–targeted agents in molecularly unselected populations,” says Tanya Dorff, MD.

Tanya Dorff, MD, discusses 3 pivotal trials—PROpel, MAGNITUDE, TALAPRO-2 trial—examining the potential of combining PARP inhibitors with androgen receptor–targeted agents in patients with metastatic castration-resistant prostate cancer. Dorff is a medical oncologist, section chief of Genitourinary Disease Program, and associate professor in the Department of Medical Oncology & Therapeutics Research at City of Hope Comprehensive Cancer Center.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.


Latest CME